last updated 09/17/2014
Annotation of European Medicines Agency (EMA) label information
for darunavir
and CYP3A4
Summary
The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.
Annotation
The EMA-approved drug darunavir is tagged with CYP3A4 in [Article:24433361].
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the darunavir EMA drug label.
*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.